Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: A multicenter, open-label single-arm study

Epilepsy Research

Volumn 63, Issue 1, 2005, Pages 1-9

  Beran, Roy G ^a   Berkovic, Samuel F ^b,c   Black, Andrew B ^d   Danta, Gytis ^e   Hiersemenzel, Reinhard ^f   Schapel, Graham J ^g   Vajda, Frank J E ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Epilepsy Research Institute   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

^e John James Memorial Hospital   (Australia)

^f UCB PHARMA   (Belgium)

^g North Coast Neurology Centre   (Australia)

Author keywords

Add on therapy; Antiepileptic drugs; Epilepsy; Levetiracetam; Partial onset seizures

Indexed keywords

ETIRACETAM;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; LETHARGY; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; NAUSEA; PARTIAL ONSET SEIZURE; PRIORITY JOURNAL; QUALITY OF LIFE; SEIZURE; SOMNOLENCE; TREATMENT OUTCOME;

EID: 13444280201     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2004.09.005     Document Type: Article

References (17)

1. -1 in adult patients with refractory epilepsy Seizure 12 2003 141 149
2. E. Ben-Menachem, U. Falter for the European Levetiracetam Study Group Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy Epilepsia 41 2000 1276 1283
3. J.J. Cereghino, V. Biton, B. Abou-Khalil, F. Dreifuss, L.J. Gauer, I. Leppik and the United States Levetiracetam Study Group Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial Neurology 55 2000 236 242
4. D. Chadwick Monotherapy clinical trials of new antiepileptic drugs: design, indications, and controversies Epilepsia 38 Suppl. 9 1997 S16 S20
5. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes Epilepsia 30 1989 389 399
6. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures Epilepsia 22 1998 489 501
7. J.A. Cramer, K. Perrine, O. Devinsky, L. Bryant-Comstock, K. Meador, and B. Hermann Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory Epilepsia 39 1998 81 88
8. J. Cramer, C. Arrigo, and G. Van Hammée Patient-rated priorities and relationship to distress in health-related quality of life domains: the QOLIE-31-P and QOLIE-10-P in a long-term levetiracetam study Epilepsia 43 Suppl. 8 2002 199
9. Data on file. UCB Pharma, Braine-l'Alleud, Belgium.
10. H. Klitgaard, A. Matagne, J. Gobert, and E. Wülfert Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy Eur. J. Pharmacol. 353 1998 191 206
11. D.-G. Margineanu, and H. Klitgaard Levetiracetam: mechanisms of action R.H. Levy R.H. Mattson B.S. Meldrum E. Perucca Antiepileptic Drugs 5th ed. 2002 Lippincott Williams & Wilkins Baltimore 419 427
12. M.J. Morrell, I. Leppik, J. French, J. Ferrendelli, J. Han, and L. Magnus The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study Epilepsy Res. 54 2003 153 161 (Corrigendum in Epilepsy Res. 56, 209-210)
13. J.-M. Nicolas, P. Collart, B. Gerin, G. Mather, W. Trager, R. Levy, and J. Roba In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent Drug Metab. Dispos. 27 1999 250 254
14. M. Noyer, M. Gillard, A. Matagne, J.-P. Hénichart, and E. Wülfert The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes Eur. J. Pharmacol. 286 1995 137 146
15. P.N. Patsalos Pharmacokinetic profile of levetiracetam: toward ideal characteristics Pharmacol. Ther. 85 2000 77 85
16. S.D. Shorvon, A. Löwenthal, D. Janz, E. Bielen, P. Loiseau for the European Levetiracetam Study Group Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures Epilepsia 41 2000 1179 1186
17. S.D. Shorvon, and K. van Rijckevorsel A new antiepileptic drug. Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug J. Neurol. Neurosurg. Psychiatry 72 2002 426 429